Syntaxin Binding Protein 5 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Syntaxin-binding protein 5 | |
|---|---|
| Protein Name | Syntaxin-binding protein 5 (Tomosyn) |
| Gene | STXBP5 |
| UniProt ID | Q9Y2W1 |
| PDB ID | 5W5D, 6CY4 |
| Molecular Weight | ~140 kDa |
| Subcellular Localization | Cytoplasm, synaptic vesicles, presynaptic terminals |
| Protein Family | LGL (Lethal giant larvae) family |
Syntaxin-binding protein 5 (STXBP5), also known as Tomosyn, is a crucial regulator of synaptic vesicle release and SNARE complex formation. Originally identified in rodents as a syntaxin-binding protein that inhibits SNARE complex assembly, Tomosyn plays a complex role in modulating neurotransmitter release by competing with synaptosome-associated protein 25 (SNAP-25) for syntaxin binding [1]. Beyond its well-characterized function in synaptic transmission, STXBP5 has been implicated in various neurological disorders including Alzheimer's disease, Parkinson's disease, and epilepsy [2].
STXBP5/Tomosyn is a large, modular protein with several distinct structural domains:
| Domain | Position | Function |
|---|---|---|
| N-terminal WD40 repeat region | aa 1-530 | Mediates protein-protein interactions; forms beta-propeller structure |
| Middle linker region | aa 531-700 | Flexible tether connecting N- and C-terminal domains |
| C-terminal R-SNARE motif | aa 701-756 | Resembles SNARE motif; forms stable complex with syntaxin |
The N-terminal WD40 repeat region adopts a seven-bladed beta-propeller structure that serves as a platform for interactions with multiple synaptic proteins including Rab3, Munc13, and RIM [3]. The C-terminal SNARE motif (also called "longin" domain) can form a ternary SNARE complex with syntaxin and SNAP-25, but this complex is non-fusogenic, thereby limiting the availability of free SNARE complexes for synaptic vesicle fusion [4].
Tomosyn functions as a molecular brake on neurotransmitter release by competing with SNAP-25 for binding to syntaxin-1. By forming a non-productive Tomosyn-syntaxin-SNAP-25 complex, it reduces the number of available SNARE complexes and thus modulates the kinetics of vesicle fusion [1].
Tomosyn interacts with Munc13 and RIM, essential proteins for synaptic vesicle priming. These interactions position Tomosyn at the active zone where it helps regulate the size of the readily releasable pool of vesicles [5].
Different isoforms of Tomosyn (generated by alternative splicing) have distinct effects on release kinetics. Tomosyn-1 is primarily inhibitory, while some splice variants may facilitate release in certain contexts [6].
STXBP5/Tomosyn has been implicated in Alzheimer's disease pathogenesis:
STXBP5 has been studied as a potential tumor suppressor:
STXBP5 represents a potential therapeutic target:
| Partner | Interaction Type | Functional Outcome |
|---|---|---|
| Syntaxin-1 | Direct binding | Inhibits SNARE complex formation |
| SNAP-25 | Part of ternary complex | Forms non-fusogenic SNARE complex |
| Munc13-1 | Direct binding | Regulates vesicle priming |
| RIM | Direct binding | Localizes to active zones |
| Rab3A | Direct binding | Modulates Tomosyn localization |
| Munc18 | Indirect | Regulates syntaxin availability |
The study of Syntaxin Binding Protein 5 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.